Caprelsa (vandetanib) / Sanofi, Esteve - LARVOL DELTA

Medullary thyroid carcinoma in clinical practice: a single-center retrospective study (ETA 2026) - "Two patients are under therapy with selpercatinib and 1 patient with vandetanib. MTC affected mostly middle-aged female patients and was hereditary in 26,9% of cases. Calcitonin was a reliable marker of MTC, unlike FNAC, which showed an inferior diagnostic yield. A significant rate of biochemical cure was attained post-operatively, while latest data showed an increase in locoregional and metastatic disease."

Retrospective data • Endocrine Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Updated Results of Randomized Phase 3 Study of Selpercatinib vs Cabozantinib or Vandetanib (C/V) in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer (MTC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. (PubMed, ESMO Open) - "The MTDs and RP2Ds of VAN + EV are 300 mg and 10 mg, respectively. VAN + EV combination is safe and active in refractory solid tumors. Further investigation is warranted in RET pathway aberrant tumors."

Clinical • Combination therapy • Journal • P1 data • Fatigue • Mucositis • Oncology • Solid Tumor • RET

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. (PubMed, J Clin Oncol) - P1/2 | "At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/vandetanib-naïve MTC and 95.8% among patients with treatment-naïve TC...The safety profile of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatment-naïve and previously treated patients with RET-mutant MTC and RET fusion-positive TC."

Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Impact of Neoadjuvant TKI Therapy on Tumor Reduction and Resectability in Locally Advanced Thyroid Carcinoma (ETA 2026) - "Therapies included selective (dabrafenib/trametinib, entrectinib, larotrectinib, selpercatinib) and multikinase inhibitors (lenvatinib, cabozantinib, vandetanib)... Neoadjuvant TKI therapy demonstrated promising results in locally advanced thyroid carcinoma, achieving high disease control rates and enabling surgical resection in over one-third of cases. Outcomes were comparable between selective and multikinase TKIs, and meaningful responses were observed across histological subtypes, although survival remained significantly longer in differentiated tumors. These findings, representing one of the largest single-center cohorts, reinforce the growing role of neoadjuvant therapy in multidisciplinary management of advanced thyroid cancer."

Clinical • Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Emergent peripheral vascular disease (PVD) in medullary thyroid carcinoma (MTC) patients treated with pralsetinib: a case series (ETA 2026) - "Two patients were previously treated with other systemic therapies before starting pralsetinib (vandetanib and vandetanib followed by cabozantinib)... Our case highlights a rare but serious adverse effect possibly associated with pralsetinib warranting increased clinical awareness and monitoring. Possible pathogenic mechanisms could be related to inhibition of fibroblast growth factor (FGF) receptor-1 inhibition or other off-target effects on FGF-23 activity leading to hyperphosphatemia. Further studies are needed to better characterize the incidence and mechanism."

Clinical • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction • Nephrology • Oncology • Peripheral Arterial Disease • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • FGF23

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. (PubMed, N Engl J Med) - P3 | "Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.)."

Journal • Metastases • P3 data • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. (PubMed, ESMO Open) - "The combination of vandetanib and everolimus showed early activity and tolerable toxicity profile in pediatric patients with advanced cancers."

Combination therapy • Journal • P1 data • Cardiovascular • Dyslipidemia • Fatigue • Hematological Disorders • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Oncology • Pediatrics • Sarcoma • Solid Tumor • Thrombocytopenia • ASPSCR1 • CDKN2A • CDKN2B • CREB3L1 • EWSR1 • KDR • TFE3

Radioembolization for Liver-Dominant Progression in Medullary Thyroid Carcinoma: A Case Report (ETA 2026) - "After vandetanib failed, selpercatinib was initiated, yielding a marked biochemical response, resulting in a favorable therapeutic response with marked biochemical improvement (calcitonin - 3532 to 2.24 pg/mL) and radiological regression. Radioembolization represents a valuable therapeutic option in selected patients, with the potential to control hepatic disease, improve symptoms, stabilize tumor markers, and extend progression free survival, while maintaining a favorable safety profile and low toxicity rates. Thus, this clinical case reinforces the role of radioembolization as a complementary strategy for patients with MTC and predominant hepatic involvement."

Case report • Clinical • Hepatology • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CEACAM5

Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (ESMO 2023) - P3 | "This study highlights the importance of selectivity in targeting RET-mutant MTC. Selpercatinib should be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC."

Clinical • Late-breaking abstract • Metastases • P3 data • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Modulation of Oxidative Stress and Metabolic Burden in Papillary Thyroid Cancer by SGLT2 and DPP-4 Inhibitors (ETA 2026) - "Two PTC (SCC147, MDA-T32) and a normal thyroid line (NTHY-ORI) were exposed for 48 hours to an SGLT2 inhibitor (10⁻⁷ M), a DPP-4 inhibitor (10⁻⁶ M), or vandetanib (10⁻⁶ M), with doses selected by MTT viability profiling...SGLT2 (10⁻⁷ M) and DPP-4 (10⁻⁶ M) inhibitors mitigated oxidative damage, modulated glucose-dependent metabolic activity and enhanced XIAP-mediated cytoprotection. However, these effects were strongly cell-linedependent."

Oxidative stress • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • XIAP

Clinical outcomes of vandetanib therapy in patients with RET-negative medullary thyroid carcinoma (ETA 2026) - "Vandetanib may represent a therapeutic option for RET(-) MTC patients. However, due to the small sample size, these results require confirmation in a larger cohort."

Clinical • Clinical data • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma

VANDETANIB-ASSOCIATED CHYLOTHORAX: A VEGF PATHWAY MEDIATED LYMPHATIC COMPLICATION (CHEST 2026) - No abstract available

Vandetanib-Associated Cutaneous Lupus (EADV 2026) - No abstract available

Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition. (PubMed, Front Mol Biosci) - "Two PTC lines (SCC147, MDA-T32) and a normal thyroid line (NTHY-ORI) were exposed for 48 h to an SGLT2 inhibitor (10-7 M), a broad, non-selective DPP inhibitor (iDPP) (10-6 M), or vandetanib (10-6 M), with doses selected by MTT viability profiling...SCC147 and NTHY-ORI exhibited marked changes in glucose-dependent metabolic indices following SGLT2 inhibition, whereas MDA-T32 showed lower glucose-dependent metabolic indices and a distinct metabolic phenotype. This divergence highlights distinct metabolic-redox vulnerabilities across thyroid cell types, underscoring the importance of cellular context in determining treatment response."

Journal • Metabolic Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • XIAP

Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC (IASLC-WCLC 2025) - P1/2 | "Most frequently received BAT were tyrosine kinase inhibitors (66.7%; 29.6% investigational agents, 25.9% cabozantinib, 7.4% vandetanib, 3.7% alectinib) and chemotherapy (25.9%)...Conclusions : This RW, multi-center study found that 2L+ treatment with pralsetinib in advanced RET fusion-positive NSCLC was associated with higher ORR and significantly improved OS and PFS compared to BAT, even after adjusting for population differences. Limitations of RW data include missing data and potential unmeasured confounding, which this study aimed to mitigate through rigorous analytical methods."

P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • RET

Circulatory compromise as a potential mechanism of fatal hepatic failure during long-term selpercatinib therapy: pharmacokinetic and clinical insights. (PubMed, Cancer Chemother Pharmacol) - "A 78-year-old man with RET-mutant medullary thyroid carcinoma received selpercatinib (160 mg twice daily) as second-line therapy following disease progression during vandetanib treatment. This case highlights a potential indirect mechanism of severe hepatic failure during long-term selpercatinib therapy, in which circulatory compromise-potentially mediated by selpercatinib-associated cardiovascular effects-may have contributed to congestive hepatic decompensation rather than direct drug-induced hepatotoxicity. These findings underscore the importance of integrating cardiovascular surveillance with hepatic monitoring during prolonged selpercatinib treatment."

Journal • PK/PD data • Cardiovascular • Hepatology • Liver Failure • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Unravelling bioanalytical innovations, degradation processes, and impurity landscapes of VEGFR inhibitors. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Bioanalysis, stability-indicating studies, and impurity profiling are used to examine chromatographic advances for VEGFR-targeted TKIs like sunitinib, pazopanib, axitinib, sorafenib, cabozantinib, vandetanib, apatinib, lenvatinib, nintedanib, and regorafenib...To ensure VEGFR-targeted TKI quality, safety, and therapeutic efficacy, LC-MS/MS for trace quantification and HRMS for structure elucidation provide a robust, future-oriented framework. To improve VEGFR-targeted TKI quality, safety, and regulatory compliance, analytical development should focus on HRMS-based impurity characterization, AI-assisted degradation prediction, green chromatography, and harmonized bioanalytical validation."

Journal • Review • KDR

Targeted Therapies in the Management of Advanced Medullary Thyroid Cancer. (PubMed, Oncologist) - "Targeted therapies have reshaped the management of advanced MTC, with selective RET inhibitors offering improved efficacy and tolerability. Continued research is essential to overcome resistance, expand therapeutic options, and improve patient outcomes."

IO biomarker • Journal • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells. (PubMed, Int J Mol Sci) - "Two PTC cell lines (MDA-T32 and SCC147) and a normal thyroid line (Nthy-ori) were analyzed for intracellular and extracellular cytokines, secretion efficiency (index), relative metabolic index (RMI), and marker of proliferation (Ki-67) expression following exposure to vandetanib (VDT), sodium-glucose cotransporter 2 (SGLT2), or dipeptidyl peptidase (DPP) inhibitors...These findings demonstrate marked heterogeneity among PTC cell lines and suggest that alterations in metabolic activity were not consistently accompanied by proportional changes in proliferative status under the experimental conditions used. VDT predominantly affected angiogenic and inflammatory signaling in MDA-T32 cells, whereas SGLT2 and DPP inhibition exerted limited measurable effects at clinically achievable concentrations."

Journal • Diabetes • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • CXCL8

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer. (PubMed, Mol Cancer Ther) - "Co-treatment with the HER2 inhibitor lapatinib, further enhanced sensitivity to vandetanib. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ patient-derived organoid and xenograft models. Future studies should evaluate if signatures predict responses in patients with ER+ breast tumors, and determine the role of co-targeting HER2 signaling with vandetanib therapy."

Journal • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

RET Alterations in Thyroid Cancer: Molecular Mechanisms, Targeted Therapies, and Emerging Resistance. (PubMed, Crit Rev Oncol Hematol) - "Previously, multikinase inhibitors, such as vandetanib and cabozantinib, were primarily used for treatment; however, their efficacy was limited due to off-target effects. Recently, selective tyrosine kinase inhibitors, including selpercatinib and pralsetinib, have been introduced, demonstrating improved selectivity and clinical efficacy...To address this issue, next-generation RET inhibitors, including zeteletinib and SYHA1815, are currently under investigation, reflecting an expanding therapeutic landscape. This article provides an overview of the molecular mechanisms of RET alterations in thyroid cancer, targeted therapies, and emerging resistance to targeted treatment."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • Thyroid Gland Papillary Carcinoma • RET

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies. (PubMed, Front Endocrinol (Lausanne)) - "Selpercatinib demonstrated the most significant PFS benefit (HR = 0.10, 95% CI: 0.05-0.18; P-score = 0.999), outperforming cabozantinib (HR = 0.28) and vandetanib (HR = 0.46)...Regarding safety, selpercatinib showed no significant difference in ≥Grade 3 AEs compared to placebo (OR = 1.34), whereas anlotinib exhibited the highest toxicity (OR = 12.00)...However, due to the heterogeneity of included populations (mixed RET mutation status and therapy lines), clinicians should interpret these findings with caution regarding the generalizability to strictly defined RET-mutant populations. Clinical decisions should be individualized.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261342793, identifier CRD420261342793."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Sulfur- and nitrogen-co-doped carbon dots derived from expired ceftriaxone powder for sensitive fluorometric and electrochemical detection of vandetanib. (PubMed, RSC Adv) - "The dual-mode platform was successfully applied to quantify VADB in pharmaceutical tablets and spiked human serum, with recoveries of 96.8-105.3% and results in good agreement with a reference HPLC-UV method. Beyond analytical performance, this work demonstrates a green, low-cost strategy that converts pharmaceutical waste into a high-value nanomaterial for reliable drug monitoring."

Journal • Oncology

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care. (PubMed, Ann Pharmacother) - No abstract available

Journal